France's Sanofi under investigation in Depakine birth defects case
Share:
PARIS (Reuters) - French healthcare company Sanofi said it had been put under investigation over a legal case relating to Depakine, a medication known to have caused birth malfunctions and slow neurological development after being taken during pregnancy.The sodium valproate, the active molecule of the drug, treats epilepsy and bipolar disorder. It has been on the market since 1967. But the drug is also known to have caused birth malfunctions and slow neurological development after being taken..